Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics

被引:0
作者
Yun Ding
Joey Paolo Ting
Jinsha Liu
Shams Al-Azzam
Priyanka Pandya
Sepideh Afshar
机构
[1] Eli Lilly and Company,Protein Engineering, Lilly Biotechnology Center
[2] Eurofins Lancaster Laboratories,Professional Scientific Services
来源
Amino Acids | 2020年 / 52卷
关键词
Non-proteinogenic amino acid; Peptide therapeutic; Discovery; Development;
D O I
暂无
中图分类号
学科分类号
摘要
With the development of modern chemistry and biology, non-proteinogenic amino acids (NPAAs) have become a powerful tool for developing peptide-based drug candidates. Drug-like properties of peptidic medicines, due to the smaller size and simpler structure compared to large proteins, can be changed fundamentally by introducing NPAAs in its sequence. While peptides composed of natural amino acids can be used as drug candidates, the majority have shown to be less stable in biological conditions. The impact of NPAA incorporation can be extremely beneficial in improving the stability, potency, permeability, and bioavailability of peptide-based therapies. Conversely, undesired effects such as toxicity or immunogenicity should also be considered. The impact of NPAAs in the development of peptide-based therapeutics is reviewed in this article. Further, numerous examples of peptides containing NPAAs are presented to highlight the ongoing development in peptide-based therapeutics.
引用
收藏
页码:1207 / 1226
页数:19
相关论文
共 1247 条
[11]  
Budisa N(2008)Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues Angew Chem Int Ed Engl 47 2595-499
[12]  
Aina OH(2013)Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints ACS Chem Biol 8 488-418
[13]  
Marik J(2006)Exenatide Am J Health Syst Pharm 63 411-765
[14]  
Liu R(2010)Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract Life Sci 86 760-18
[15]  
Lau DH(2020)Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist Diabetes Technol Ther 22 10-1340
[16]  
Lam KS(2018)Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist Sci Transl Med 10 eaar7047-1702
[17]  
Albert R(1996)How structural features influence the biomembrane permeability of peptides J Pharm Sci 85 1336-2650
[18]  
Marbach P(2011)Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials J Clin Endocrinol Metab 96 1695-E3454
[19]  
Bauer W(1997)The mechanism of ACV synthetase Chem Rev 97 2631-1342
[20]  
Briner U(2017)Peptibodies: an elegant solution for a long-standing problem Biopolymers 110 e23095-11375